ALK and non-small cell lung carcinoma: Crizotinib, a selective small-molecule tyrosine kinase inhibitor (TKI) of cMET, anaplastic lymphoma kinase (ALK), and reactive oxygen species (ROS1) is approved for ALK or ROS1-positive metastatic non-small cell lung cancer (23, 24).